Page 31 - Merck Sharp News Today

Adjuvant pembrolizumab provides a continued benefit for patients with stage IIB or IIC melanoma at 3 years, updated data suggest.

In this article, we will be covering the top 16 medicine producing countries in the world. If you want to skip our detailed analysis of the pharmaceutical industry and emerging trends, go directly to the Top 5 Medicine Producing Countries in the World. The global pharmaceutical industry is forecasted to grow from $1.4 billion in […]

/PRNewswire/ -- DelveInsights Antibody-drug Conjugates Competitive Landscape – 2023 report provides comprehensive global coverage of available, marketed,...

This randomized clinical trial examines the efficacy and safety of once-weekly icodec vs once-daily insulin degludec in people with insulin-naive type 2 diabet

Potent antivirals to combat some of the most serious diseases facing humanity June 2023 Nasdaq: COCP www.cocrystalpharma.com ...

SCYNEXIS (NASDAQ:SCYX – Get Rating) and Antibe Therapeutics (OTCMKTS:ATBPF – Get Rating) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, profitability, earnings, dividends, institutional ownership, analyst recommendations and risk. Institutional & Insider Ownership 48.0% of SCYNEXIS shares are held […]

SAN DIEGO — Adults with obesity and type 2 diabetes achieved a 14.7% weight loss at 72 weeks with 15 mg tirzepatide, according to data from the SURMOUNT-2 trial presented at the American Diabetes Association Scientific Sessions.In a phase 3 randomized controlled trial, more than 60% of adults with obesity and type 2 diabetes lost at least 10% of their body weight at 72 weeks if they were

Combination pembrolizumab and axitinib continues to show superior efficacy to sunitinib in advanced clear cell renal cell carcinoma.

Nearly 60% of health care providers surveyed failed to choose the same treatment strategies for HER2–early breast cancer.

Positive decision grants permission for NOX-A12 to be evaluated in clinical trial in the US in addition to EuropeBERLIN--(BUSINESS WIRE)--Regulatory News:TME Pharma N.V. (Euronext Growth Paris: ALTME), a biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microe...